Catabasis Pharma's Phase 3 DMD Trial Exceeds Target Enrollment; Stock Up 5%

Shares of Catabasis Pharmaceuticals Inc. (CATB) are up over 5% in premarket trading on Tuesday, following the completion of enrollment in the Company's phase III trial of Edasalonexent in Duchenne muscular dystrophy.

from RTT - Biotech https://ift.tt/2nhs7R9
via IFTTT